WallStreetZenWallStreetZen

NASDAQ: PCRX
Pacira Biosciences Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PCRX past earnings growth

How has PCRX's earnings growth performed historically?
Company
N/A
Industry
18.65%
Market
117.76%
PCRX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PCRX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PCRX past revenue growth

How has PCRX's revenue growth performed historically?
Company
1.88%
Industry
9.98%
Market
15.15%
PCRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PCRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PCRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PCRX earnings and revenue history

Current Revenue
$681.8M
Current Earnings
$70.5M
Current Profit Margin
10.3%

PCRX Return on Equity

Current Company
8.3%
Current Industry
13.8%
Current Market
28.2%
PCRX's Return on Equity (8.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PCRX announces earnings.

PCRX Return on Assets

Current Company
4.5%
Current Industry
3.8%
PCRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PCRX Return on Capital Employed

Current Company
7.78%
Current Industry
5.7%
PCRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PCRX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PCRX$681.75M$190.25M$70.47M+14.01%+54.98%
DVAX$236.15M$22.19M$9.22M+76.45%-71.80%
AVDL$55.14M-$145.72M-$156.83M-8.59%N/A
TLRY$743.25M-$186.62M-$351.95M+30.54%N/A
ANIP$517.46M$128.31M$33.92M+20.00%+6.72%
View Top Pharmaceutical Stocks

Pacira Biosciences Earnings & Revenue FAQ

What were PCRX's earnings last quarter?

On Invalid Date, Pacira Biosciences (NASDAQ: PCRX) reported Q1 2024 earnings per share (EPS) of $0.19, up 144.19% year over year. Total Pacira Biosciences earnings for the quarter were $8.98 million. In the same quarter last year, Pacira Biosciences's earnings per share (EPS) was -$0.43.

If you're new to stock investing, here's how to buy Pacira Biosciences stock.

What was PCRX's earnings growth in the past year?

As of Q2 2024, Pacira Biosciences's earnings has grown year over year. Pacira Biosciences's earnings in the past year totalled $70.47 million.

What was PCRX's revenue last quarter?

On Invalid Date, Pacira Biosciences (NASDAQ: PCRX) reported Q1 2024 revenue of $167.12 million up 4.23% year over year. In the same quarter last year, Pacira Biosciences's revenue was $160.34 million.

What was PCRX's revenue growth in the past year?

As of Q2 2024, Pacira Biosciences's revenue has grown 1.88% year over year. This is 8.1 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Pacira Biosciences's revenue in the past year totalled $681.75 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.